Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Non-Current Assets (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Non-Current Assets data on record, last reported at $44.9 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 10.4% year-over-year to $44.9 million; the TTM value through Dec 2025 reached $188.5 million, down 9.82%, while the annual FY2025 figure was $44.9 million, 10.4% down from the prior year.
  • Non-Current Assets reached $44.9 million in Q4 2025 per TNGX's latest filing, down from $46.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $166.8 million in Q2 2021 and bottomed at $7.8 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $56.6 million, with a median of $52.3 million recorded in 2024.
  • The widest YoY moves for Non-Current Assets: up 682.88% in 2022, down 93.48% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $7.8 million in 2021, then surged by 682.88% to $61.2 million in 2022, then dropped by 8.45% to $56.0 million in 2023, then dropped by 10.49% to $50.1 million in 2024, then dropped by 10.4% to $44.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $44.9 million in Q4 2025, $46.4 million in Q3 2025, and $47.8 million in Q2 2025.